

**Wright Medical Group N.V.**  
**Supplemental Net Sales Information**  
(unaudited)

**Three months ended June 25, 2017 net sales growth/(decline)**

<b>Product line</b>	<b><u>U.S. as reported</u></b>	<b><u>Int'l constant currency</u></b>	<b><u>Int'l as reported</u></b>	<b><u>Global constant currency</u></b>	<b><u>Global as reported</u></b>
Lower extremities	4%	(5%)	(9%)	2%	1%
Upper extremities	15%	(1%)	(4%)	10%	9%
Biologics	8%	8%	5%	8%	8%
Sports med & other	(18%)	7%	2%	(2%)	(5%)
<b>Total net sales</b>	9%	(1%)	(4%)	6%	5%

**Six months ended June 25, 2017 net sales growth/(decline)**

<b>Product line</b>	<b><u>U.S. as reported</u></b>	<b><u>Int'l constant currency</u></b>	<b><u>Int'l as reported</u></b>	<b><u>Global constant currency</u></b>	<b><u>Global as reported</u></b>
Lower extremities	2%	(7%)	(11%)	0%	(1%)
Upper extremities	14%	4%	1%	11%	10%
Biologics	9%	15%	14%	10%	10%
Sports med & other	(10%)	4%	(2%)	(1%)	(5%)
<b>Total net sales</b>	8%	2%	(2%)	6%	5%

**Wright Medical Group N.V.**

**Reconciliation of Adjusted Non-GAAP Earnings Per Share to Net Loss from Continuing Operations Per Share**

(dollars in thousands, except per share data--unaudited)

	Three months ended		Six months ended	
	June 25, 2017	June 26, 2016	June 25, 2017	June 26, 2016
<b>Net loss from continuing operations, as reported</b>	\$ (20,960)	\$ (42,031)	\$ (57,667)	\$ (82,223)
<b>Net loss from continuing operations per share, as reported</b>	\$ (0.20)	\$ (0.41)	\$ (0.55)	\$ (0.80)
Reconciling items:				
Inventory step-up amortization	—	10,387	—	20,616
Non-cash interest expense on convertible notes <sup>1</sup>	11,249	8,240	22,248	15,296
Non-cash loss on extinguishment of debt	—	12,343	—	12,343
Derivatives mark-to-market adjustments <sup>2</sup>	(4,329)	(16,632)	(3,964)	(23,273)
Transaction and transition costs	3,201	9,014	6,173	19,847
Management changes	—	1,348	—	1,348
CVR mark-to-market adjustments <sup>2</sup>	(3,924)	1,401	2,236	6,725
Contingent consideration fair value adjustment <sup>2</sup>	176	306	176	306
Legal settlement	—	1,800	—	1,800
Costs associated with 2021 Notes issuance	—	234	—	234
IRS settlement <sup>3</sup>	—	(3,073)	—	(3,073)
Tax effect of reconciling items <sup>4</sup>	(52)	(2,132)	(70)	(3,321)
<b>Non-GAAP net loss from continuing operations, as adjusted</b>	\$ (14,639)	\$ (18,795)	\$ (30,868)	\$ (33,375)
Add back amortization of intangible assets	6,999	7,484	14,396	13,941
<b>Adjusted non-GAAP earnings</b>	\$ (7,640)	\$ (11,311)	\$ (16,472)	\$ (19,434)
Weighted-average basic shares outstanding	104,377	102,785	104,020	102,745
<b>Adjusted non-GAAP earnings per share</b>	\$ (0.07)	\$ (0.11)	\$ (0.16)	\$ (0.19)

<sup>1</sup> Impacting interest expense, net

<sup>2</sup> Impacting other (income) expense, net

<sup>3</sup> IRS Settlement includes \$0.8 million of interest income and \$2.3 million tax benefit.

<sup>4</sup> Determined based upon the effective tax rate in the jurisdiction in which the expense was incurred.

**Wright Medical Group N.V.**  
**Reconciliation of Non-GAAP Adjusted EBITDA to Net Loss from Continuing Operations**  
(dollars in thousands--unaudited)

	Three months ended		Six months ended	
	June 25, 2017	June 26, 2016	June 25, 2017	June 26, 2016
<b>Net loss from continuing operations</b>	\$ (20,960)	\$ (42,031)	\$ (57,667)	\$ (82,223)
Interest expense, net	18,339	13,024	36,534	24,878
Provision (benefit) from income taxes	385	(3,300)	1,324	(4,588)
Depreciation	13,678	13,270	27,124	26,120
Amortization	6,999	7,484	14,396	13,941
<b>Non-GAAP EBITDA</b>	<b>\$ 18,441</b>	<b>\$ (11,553)</b>	<b>\$ 21,711</b>	<b>\$ (21,872)</b>
Reconciling items impacting EBITDA:				
Non-cash share-based compensation expense	4,732	3,056	8,686	6,373
Other (income) expense, net	(6,557)	(2,061)	1,418	(3,129)
Inventory step-up amortization	—	10,387	—	20,616
Transaction and transition costs	3,201	9,014	6,173	19,847
Management changes	—	1,348	—	1,348
Legal settlement	—	1,800	—	1,800
Costs associated with 2021 Notes issuance	—	234	—	234
<b>Non-GAAP adjusted EBITDA</b>	<b>\$ 19,817</b>	<b>\$ 12,225</b>	<b>\$ 37,988</b>	<b>\$ 25,217</b>
Net sales from continuing operations	179,693	170,716	356,884	340,007
<b>Non-GAAP adjusted EBITDA margin</b>	<b>11.0%</b>	<b>7.2%</b>	<b>10.6%</b>	<b>7.4%</b>

**Wright Medical Group N.V.**  
**Reconciliation of Non-GAAP Adjusted Gross Margins to Gross Margins from Continuing Operations**  
(dollars in thousands--unaudited)

	Three months ended		Six months ended	
	June 25, 2017	June 26, 2016	June 25, 2017	June 26, 2016
<b>Gross profit from continuing operations, as reported</b>	\$ 141,571	\$ 121,707	\$ 281,636	\$ 244,332
<b>Gross margins from continuing operations, as reported</b>	78.8 %	71.3 %	78.9 %	71.9 %
Reconciling items impacting gross profit:				
Inventory step-up amortization	—	10,387	—	20,616
Transaction and transition costs	—	1,954	685	2,078
<b>Non-GAAP gross profit from continuing operations, as adjusted</b>	<b>\$ 141,571</b>	<b>\$ 134,048</b>	<b>\$ 282,321</b>	<b>\$ 267,026</b>
Net sales from continuing operations	179,693	170,716	356,884	340,007
<b>Non-GAAP adjusted gross margins from continuing operations</b>	<b>78.8%</b>	<b>78.5%</b>	<b>79.1%</b>	<b>78.5%</b>

**Wright Medical Group N.V.**  
**Reconciliation of Other Non-GAAP Financial Measures to Other As Reported Results**  
(dollars in thousands--unaudited)

	Three months ended		Six months ended	
	June 25, 2017	June 26, 2016	June 25, 2017	June 26, 2016
<b>Net sales</b>	\$ 179,693	\$ 170,716	\$ 356,884	\$ 340,007
<b>Selling, general and administrative expense, as reported</b>	\$ 130,818	\$ 136,483	\$ 260,652	\$ 271,229
Selling, general and administrative expense as a percentages of net sales, as reported	72.8 %	79.9 %	73.0 %	79.8 %
Reconciling items impacting selling, general and administrative expense:				
Transaction and transition costs - selling, general and administrative	3,101	6,970	5,388	17,530
Management changes	—	1,348	—	1,348
Legal settlement	—	1,800	—	1,800
Costs associated with 2021 Notes issuance	—	234	—	234
<b>Selling, general and administrative expense, as adjusted</b>	<b>\$ 127,717</b>	<b>\$ 126,131</b>	<b>\$ 255,264</b>	<b>\$ 250,317</b>
<b>Selling, general and administrative expense as a percentage of net sales, as adjusted</b>	<b>71.1%</b>	<b>73.9%</b>	<b>71.5%</b>	<b>73.6%</b>
<b>Research &amp; development expense, as reported</b>	\$ 12,547	\$ 12,108	\$ 24,979	\$ 24,224
Research & development expense as a percentages of net sales, as reported	7.0 %	7.1 %	7.0 %	7.1 %
Reconciling items impacting research & development expense:				
Transaction and transition costs - research & development	100	90	100	239
<b>Research &amp; development expense, as adjusted</b>	<b>\$ 12,447</b>	<b>\$ 12,018</b>	<b>\$ 24,879</b>	<b>\$ 23,985</b>
<b>Research &amp; development expense as a percentage of net sales, as adjusted</b>	<b>6.9%</b>	<b>7.0%</b>	<b>7.0%</b>	<b>7.1%</b>